CO-BONA
18.3.2024 09:06:33 CET | Business Wire | Press release
Today, Bona® announced that four of its products are now certified by the U.S. Environmental Protection Agency (EPA) Safer Choice program and have earned the Safer Choice label. The new certification applies to the Bona Pet System™ including Bona Pet System™ Hard-Surface Floor Deep Cleaner and Bona Pet System™ Wood Floor Deep Cleaner as well as Bona’s OxyPower floor cleaners -- Bona OxyPower Hard-Surface Floor Deep Cleaner and Bona OxyPower Wood Floor Deep Cleaner. Safer Choice is a voluntary EPA program that certifies cleaning and other products made with ingredients that are safer for people, pets, and the planet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318768884/en/
Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification (Graphic: Business Wire)
“As we continue our journey to innovate cleaning solutions that bring out the beauty in floors, our primary focus is to leverage the latest technologies and research when it comes to ingredients,” said Marie Shore, Director Product Management EMEA & APAC, Bona.“Recognition like this one from the EPA Safer Choice program is a key milestone in validating our work for a more sustainable future.”
The Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. Every ingredient in products that carry the Safer Choice label is reviewed by EPA scientists to make sure certified products only contain the safest possible ingredients for people and the planet. Safer Choice-certified products are made with ingredients that won't cause serious health problems, like cancer, and aren't harmful to fish or waterways. Safer Choice also restricts volatile organic compounds to minimize indoor air pollution and associated respiratory concerns. Products with the label also use more sustainable packaging that doesn't contain toxic chemicals, like heavy metals.
Powered by hydrogen peroxide, Bona OxyPower Wood Floor Deep Cleaner and Bona OxyPower Hard-Surface Floor Deep Cleaner are specifically designed to remove heavy dirt build-up, providing a deep clean for wood or hard-surface floors. The ready-to-use, oxygenated, waterbased formula releases thousands of micro-bubbles that loosen heavy dirt build-up, removes stuck-on messes, and lifts away stains via a bubbling action to provide a deep clean for floors.
Formulated specifically for cleaning pet messes, The Bona Pet System Hard Surface Floor Deep Cleaner and Bona Pet System Wood Floor Deep Cleaner offer a deep clean by penetrating through tough stuck-on stains, tracked in dirt, and accident messes with the cleaning power of Hydrogen Peroxide. The Odour Guard Technology™ eliminates and neutralizes urine and other organic odours upon contact.
For more information about Bona Pet System and OxyPower cleaners are visit www.bona.com. These GREENGUARD certified products are available in EMEA and APAC regions.
“These four cleaning products were developed to meet the high standards of consumers as well as certifying organizations like the EPA Safer Choice program,” continued Shore. “With 11 Safer Choice certified products in North America it made sense to seek this certification for our products in Europe. It all aligns to our long-standing mission to minimize our environmental impact by innovating safer systems and products to the highest sustainability standards.”
About the EPA Safer Choice Program
Safer Choice incentivizes safer, greener chemistry by allowing companies to differentiate their products in the marketplace with the Safer Choice label. With thousands of certified products, the Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. For more information about the Safer Choice program, visit: www.epa.gov/saferchoice.
About Bona®
Bona® is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 4.1bn SEK (EUR 366million) 2023. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318768884/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom